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Abstract The aim of this study was to investigate the
association between caffeine consumption and headache
type and frequency in the general adult population. The
results were based on cross-sectional data from 50,483
(55%) out of 92,566 invited inhabitants aged C20 years
who participated in the Nord-Trøndelag Health Survey.
In the multivariate analyses, adjusting for age, gender,
smoking, and level of education as confounding factors, a
weak but significant association (OR = 1.16, 95% CI
1.09–1.23) was found between high caffeine consumption
and prevalence of infrequent headache. In contrast, head-
ache [14 days/month was less likely among individuals
with high caffeine consumption compared to those with
low caffeine consumption. The results may indicate that
high caffeine consumption changes chronic headache into
infrequent headache due to the analgesic properties of
caffeine. Alternatively, chronic headache sufferers tend to
avoid intake of caffeine to not aggravate their headaches,
whereas individuals with infrequent headache are less
aware that high caffeine use can be a cause.
Keywords Migraine  Headache  Epidemiology 
Norway
Introduction
Caffeine is probably the most commonly consumed
stimulant worldwide, generating increased wellbeing,
happiness, energy, alertness, and sociability [1]. Caffeine
also has acute analgesic properties and promotes headache
relief [2]. On the other hand, among habitual caffeine
users, abrupt cessation may results in time-limited with-
drawal symptoms such as headache [1]. In a placebo-
controlled double-blind study, as many as 52% of the
participants had a moderate or severe headache within the
first 2 days of cessation of coffee intake, whereas only 6%
had similar headache among those who continued the
coffee intake [3]. However, more recently, a controlled,
blinded study reported a lower prevalence (33%) of caf-
feine-withdrawal headache [4].
Conflicting results have also been found in population-
based studies evaluating the association between caffeine
and headache. Some studies have reported a positive
relationship between high caffeine consumption and prev-
alence of headache [5], migraine [6], and chronic migraine
[7]. Furthermore, high caffeine consumption has been
found to be a modest risk factor for onset of chronic daily
headache [8].
In contrast, no clear relationship has been found
between current caffeine consumption and headache [9] or
chronic headache [8, 10]. The prevalence of caffeine-
withdrawal headache in a Norwegian population-based
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survey was only 0.4% [11]. In previous case-control studies
the total number of participants has been \900 [7, 8, 10],
and\6,000 in previous cross-sectional studies [5, 6, 9, 11].
Recent reviews of headache epidemiology and health
economy have showed that headache constitutes consid-
erable burden on individuals and society [12, 13]. The high
prevalence of both headache and caffeine consumption
means that even if caffeine is a weak causal factor for
headache, this could be of great importance for the public
health. Because of divergent results and limited number of
participants in previous studies, a study including[50,000
participants should be of interest.
The aim of this large-scale cross-sectional population-
based survey was to evaluate the association between
caffeine consumption and headache type and frequency.
Materials and methods
Study population
The 1995–1997 HUNT (HUNT 2) study covered a wide
range of topics in two questionnaires. The first question-
naire (Q1) was enclosed with the invitation letter and
completed at home and delivered during attendance at the
health examination. Q1 included three questions about
caffeine consumption. The second questionnaire (Q2),
which also included questions about headache and ergot-
amine intake, was filled in after the examination and
returned by mail. Of the 92,566 invited inhabitants, a total
of 51,383 subjects (56%) completed the headache ques-
tionnaire [14], whereof 50,483 (55%) answered the
question about caffeine consumption. Details of the non-
participants are described elsewhere [14, 15].
The study was approved by the Regional Committee for
Ethics in Medical Research, and the HUNT Study is also
approved by the Norwegian Data Inspectorate.
Estimation of caffeine consumption
The participants were asked to report the number of cups of
brew coffee, other types of coffee (i.e. instant coffee and
drip coffee), and tea per day. Based on previous data from
Norway [16], the estimated caffeine content per cup was
90 mg for brew coffee, 80 mg for other types of coffee,
and 50 mg for tea [16]. Headache patients were asked to
report the number of ergotamine tablets and suppositories
(Cafergot and Anervan) used during the past month. The
caffeine content for Cafergot was 100 mg, for Anervan
suppository 100 mg, and for Anervan tablets 50 mg. The
caffeine consumption per day due to use of ergotamine
medication was calculated by dividing the total amount of
caffeine due to ergotamine intake by 30. Total overall
caffeine consumption (mg/day) was the sum of caffeine
per day due to brew coffee, other types of coffee, tea, and
ergotamine-containing medication.
Information regarding caffeine consumption due to
caffeinated soda, hot chocolate, and other caffeine-
containing medications (OTC or prescribed) were not
available.
Headache diagnosis
The headache questions in Q2 and the prevalence of
headache are published elsewhere [14, 15]. The headache
questions were designed mainly to determine whether or
not the person had headache, and the frequency of head-
ache, and to diagnose migraine according to a modified
version of the migraine criteria of the Headache Classifi-
cation Committee of the IHS [17]. Subjects who answered
‘‘yes’’ to the question ‘‘Have you suffered from headache
during the last 12 months?’’ were classified as headache suf-
ferers. Based on data from the subsequent 12 headache
questions, they were classified into two groups of either
migraine or non-migrainous headache. The diagnoses were
mutually exclusive. A headache which did not fulfil the
criteria for migraine was classified as a non-migrainous
headache. Based on a question about headache frequency
during the last year, headache frequency was divided in three
categories;\7, 7–14, and[14 days/month.
The classification of the subjects has been described in
detail previously, and has been validated by interview
diagnoses [18]. In short, for migraine, the positive predic-
tive value (PPV) was 84% and the negative predictive
value (NPV) was 78%; for non-migrainous headache, the
PPV was 68% and the NPV was 76% [16]. For the ques-
tionnaire-based diagnosis of migraine with aura, the PPV
and specificity were 100%, whereas the NPV was 91% and
sensitivity was 42% [18].
Statistics
Differences between continuous variables were tested with
one-way analyses of variance and between proportions
by Chi-squared test. In the multivariate analyses, using
logistic regression, we estimated the prevalence odds ratio
(OR) with 95% confidence interval (CI) for the association
between headache and caffeine consumption. The partici-
pants were categorized into quartiles based on individual
values of total caffeine consumption. High caffeine con-
sumption was defined as the top quartile ([540 mg/day),
whereas low caffeine consumption was defined at the low
quartile (0–240 mg/day). Separate analyses for dietary
caffeine consumption (excluding caffeine due to use of
ergotamine-containing medication) were also done. A large
number of confounders were evaluated, e.g. current
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smoking as it reduces the halftime of caffeine with 30–50%
[19], and use of oral contraceptives in women because they
increase the level of caffeine with as much as 50% [20]. In
the final analyses we adjusted for age, gender, smoking,
and education level as confounders. Other potential con-
founding factors like physical activity, previous myocardial
infarction, alcohol consumption, body mass index, and
mean systolic blood pressure were also evaluated, but were
excluded from the final analyses because they changed the
OR by\5%. When appropriate, caffeine consumption was
also treated as a continuous variable and was incorporated
in a two sided test for trend to evaluate the probability of a
linear relationship between caffeine consumption and
headache. We also investigated potential interaction
between age and caffeine consumption by including the
product of the two variables into the logistic regression
analyses. The interaction coefficient was tested using Wald
v2 statistics. Data analyses were performed with the
Statistical Package for the Social Sciences, version 15.0
(SPSS, Chicago, IL, USA).
Results
Among the 50,483 participants answering questions about
caffeine consumption and headache, 19,577 (38.8%) suf-
fered from headache past year; 6,131 (12.1%) from
migraine, and the remaining 13,446 (26.6) from non-
migrainous headache. A total of 1,163 reported headache
[14 days/month, whereof 511 (1.0%) probably had med-
ication overuse headache (MOH) as defined in a previous
paper [21].
Average dietary caffeine consumption in the general
population was 426 mg/day (median 400 mg/day), whereas
the average caffeine consumption due to ergotamine intake
was 1.4 mg/day (median 0 mg/day) among migraineurs.
As demonstrated by Fig. 1, average total caffeine con-
sumption was higher among men than women both in
headache sufferers and headache-free individuals.
Table 1 presents the demographic data and clinical
characteristics for the caffeine consumption groups.
Among individuals with the lowest caffeine consumption,
Headache days per month

































Fig. 1 Mean daily caffeine consumption with 95% confidence
interval (CI) among men and women related to headache frequency
Table 1 Background data on participants according to use of caffeine
Variables 0–240 mg Caffeine 241–400 mg Caffeine 401–540 mg Caffeine [540 mg Caffeine Missing data
n 12,190 15,211 10,935 12,147 900
Gender, female (%) 59.6 55.8 53.8 45.5 59.0
Mean age (SD) 44.6 (19.3) 51.9 (16.7) 51.2 (15.5) 47.3 (13.7) 60.9 (18.1)
Years of education C13 (%) 27.2 21.4 18.2 14.4 5.6
Mean BMI (SD) 26.0 (4.2) 26.5 (4.0) 26.5 (4.0) 26.4 (4.0) 26.8 (4.5)
Current smoking (%) 13.9 19.8 29.6 49.1 29.0
High physical activity levela (%) 10.8 7.4 7.6 9.0 3.6
Alcohol abstainers (%) 15.4 13.0 11.2 7.5 19.7
Previous myocardial infarction 2.9 3.6 3.3 2.6 5.7
Mean systolic blood pressure (SD) 135 (22) 140 (23) 139 (22) 136 (20) 146 (26)
Oral contraceptives (%)b 22.3 9.6 6.5 5.7 11.0
Chronic musculoskeletal complaintsc 40.8 47.1 48.4 50.4 47.7
a High physical activity level = C3 h/week with hard physical activity
b Use of oral contraceptives among women \57 years
c Chronic musculoskeletal complaints = pain and/or stiffness in muscles and joints C3 months during the past year
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educational level, level of physical activity, proportion of
alcohol abstainers, and proportion of women were signifi-
cantly higher (P \ 0.001) compared to those with higher
consumption, whereas, age, proportion of smokers, and
prevalence of chronic musculoskeletal complaints were
significantly lower (P \ 0.001, Table 1). In particular, a
low mean age (36.1 years) was found among the minor
group of 2,646 (5.2% out of the 50,483 participants) who
did not report intake of coffee or tea.
The unadjusted headache prevalence varied with daily
caffeine consumption being highest for the group of indi-
viduals using [500 mg caffeine daily (Fig. 2). In the
multivariate analyses, adjusting for age, gender, smoking,
and level of education as confounding factors, the preva-
lence of headache was higher among individuals with the
highest caffeine consumption than among individuals with
the lowest consumption (OR = 1.13, 95% CI 1.07–1.20)
(Table 2), evident for both men (OR = 1.17, 95% CI 1.06–
1.28) and women (OR = 1.13, 95% CI 1.03–1.23) (data
not shown). The results were more marked for non-
migrainous headache (OR = 1.14, 95% CI 1.07–1.21) than
migraine (OR = 1.10, 95% CI 1.01–1.20) (Table 2). No
interaction between age and caffeine consumption was
found (P = 0.66). Our results did not change if only die-
tary caffeine consumption was evaluated (data not shown).
As displayed in Table 3, individuals with high caffeine
consumption were more likely to have headache \7 days/
month than those with low caffeine consumption, and there
was a linear trend (P \ 0.001) of increasing prevalence of
headache \7 days/month with increasing caffeine con-
sumption (Table 3). Non-migrainous headache \7 days/
month was 18% more common (OR = 1.18, 95% CI 1.10–
1.26) among individuals with high caffeine consumption
than among individuals with lowest consumption, evident
for both men (OR = 1.21, 95% CI 1.09–1.34) and women
(OR = 1.16, 95% CI 1.06–1.28). In contrast, headache
[14 days/month was less likely among individuals with
intermediate or high caffeine consumption compared to
those with low caffeine consumption (Table 3). Because
information about use of caffeine-containing OTC medi-
cation was not available, we repeated our analyses
adjusting for the diagnosis of probable MOH, but these
adjustments did not change the results substantially (data
not shown).
Discussion
In this large-scale cross-sectional population-based study a
weak but significant association was found between high
caffeine consumption and migraine and non-migrainous
headache, most evident among individuals with infrequent
headache. Surprisingly, chronic headache was more pre-
valent among individuals with low caffeine consumption.
Mean estimated daily caffeine consumption of 426
mg/day was nearly identical with the figures found previ-
ously in Sweden (407 mg/day) and in Norway (400 mg/day)
[22]. Because the mean daily caffeine consumption in
Scandinavian countries is approximately twice as high as in
other countries in Europe and in the US, direct comparison
of our results with other studies should be done with
some caution. However, in the present study headache,
including migraine, was 1.1 times more likely (i.e. 10%
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Fig. 2 Unadjusted headache prevalence (%) related to daily caffeine
consumption
Table 2 Prevalence OR of headache related to use of caffeine
Variables Total Headache Migraine Non-migrainous headache
51,383 % OR (CI) % OR (CI) % OR (CI)
Use of caffeine
0–240 12,190 39.8 1.00 (reference) 12.7 1.00 (reference) 27.1 1.00 (reference)
241–400 mg 15,211 36.1 0.96 (0.91–1.00) 11.7 1.02 (0.94–1.10) 24.4 0.94 (0.88–0.99)
401–540 mg 10,935 37.3 0.97 (0.92–1.03) 11.7 1.00 (0.92–1.10) 25.6 0.96 (0.90–1.03)
[540 mg 12,147 42.2 1.13 (1.07–1.20) 12.6 1.10 (1.01–1.20) 29.9 1.14 (1.07–1.21)
Missing 900 29.4 0.90 (0.77–1.06) 8.7 0.95 (0.73–1.23) 20.8 0.90 (0.75–1.08)
P trend value P \ 0.001 P = 0.02 P \ 0.001
OR adjusted for age, gender, smoking, and level of education
156 J Headache Pain (2009) 10:153–159
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consumption. Somewhat stronger associations were repor-
ted in the cross-sectional studies from Australia (headache
1.3 times more likely) and Japan (migraine 2.4 times more
likely) [5, 6]. On the other hand, no clear relationship was
found between current caffeine consumption and headache
in a cross-sectional study from England [9] and in two case-
control studies focusing on chronic headache [8, 10].
However, the high prevalence of headache and caffeine
consumption means that even if the effect of caffeine con-
sumption on headache prevalence is modest, a reduction could
potentially have a large impact on the absolute number of
individuals with headache. Thus, based on our results, well
designed studies should address the hypothesis that a decrease
in caffeine consumption alleviates headache complaints.
Interestingly, when headache frequency was considered,
we found that non-migrainous headache \7 days/month
was 18% more likely among individuals with high caffeine
consumption than among those with lowest consumption.
Since the study is cross-sectional, it cannot be concluded
that high caffeine consumption causes infrequent headache.
There may be a reverse causation, i.e. that some use caf-
feine to relieve their headache. In addition, although we
adjusted for many known confounders, some residual
confounding can never be totally excluded. There may be
other incompletely registered factors, like sleep disorders,
anxiety and other psychological problems which could
influence our findings. However, if the association is a
causal one, it seems that high caffeine consumption has a
higher impact on headache prevalence than previously
reported in Va˚ga˚ in Norway, indicating a prevalence of
caffeine-withdrawal headache of only 0.4% [11]. One
interpretation of this difference is that caffeine may cause
headache not only in connection with withdrawal.
Surprisingly, chronic headache was most likely among
individuals with low caffeine consumption. It should be
emphasized that the great majority (78%) of these reported
intake of coffee and/or tea on a daily basis, and the mean
caffeine consumption being 125 mg/day in this group. This
low value is of relevance because withdrawal of a main-
tenance dose of 100 mg caffeine has been shown to induce
headache in a double-blind experiment [23]. Similarly,
significant reduction of caffeine consumption is also
associated with headache [23] which may be of relevance
because the low caffeine consumption group may partly
consist of individuals who recently had reduced their caf-
feine consumption. Thus, one can not rule out the
possibility that caffeine intake may be a contributing factor
for chronic headache in this group.
However, there is no obvious reason why chronic
headache was less likely among individuals with interme-
diate or high caffeine consumption. A possible explanation
could be that medium and high caffeine consumption
change chronic headache into infrequent headache due to
the analgesic properties of caffeine [2]. On the other hand,
another quite opposite explanation could be that many
chronic headache sufferers had experienced the headache
precipitating properties of coffee and therefore reduced
their intake, whereas individuals with infrequent headache
were less aware that high caffeine consumption can be the
cause. This may be analogous to the findings that migrai-
neurs tend to avoid alcohol, to avoid its headache-
triggering effect [24].
A potential weakness of the present study is that infor-
mation regarding caffeine consumption due to caffeinated
soda, chocolate, and caffeine-containing OTC medication
was not available. Our results are probably most valid for
individuals with headache \7 days/month, because use of
analgesics containing caffeine was most likely relatively
low in this group, whereas such use was probably relatively
high among individuals with chronic headache. In the
period between 1995 and 1997, the sale of analgesics
containing caffeine was approximately five defined daily
doses/1,000 inhabitants/day in Norway [25]. Although our
results did not change when adjusting for the diagnosis
MOH, we cannot rule out that information about caffeine
containing analgesics could have changed our results for
Table 3 Prevalence OR of headache related to use of caffeine
Variables Total Headache \7 days/week Headache 7–14 days/week Headache [14 days/week
51,383 % OR (CI) % OR (CI) % OR (CI)
Use of caffeine
0–240 mg 12,190 31.6 1.00 (reference) 5.5 1.00 (reference) 2.7 1.00 (reference)
241–400 mg 15,211 29.2 0.99 (0.94–1.05) 4.9 0.96 (0.86–1.08) 1.9 0.63 (0.53–0.74)
401–540 mg 10,935 30.4 1.02 (0.96–1.08) 4.9 0.92 (0.81–1.04) 2.0 0.63 (0.52–0.75)
[540 mg 12,147 33.8 1.16 (1.09–1.23) 6.0 1.12 (0.99–1.26) 2.6 0.82 (0.69–0.98)
Missing 900 21.1 0.85 (0.71–1.02) 5.4 1.21 (0.88–1.66) 2.9 0.85 (0.56–1.30)
P trend value P \ 0.001 P = 0.13 P = 0.09
OR adjusted for age, gender, smoking, and level of education
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headache[6 days/month. The caffeine consumption due to
caffeinated soda and chocolate in Nord-Trøndelag County
was not estimated. It should be emphasized that the
chocolate consumption per inhabitants is higher in Norway
than in most other countries. However, the caffeine content
in caffeinated soda and chocolate is much lower than in e.g.
coffee [26], and has been reported to be below 5% of the
total caffeine consumption in other studies from Norway
and Sweden [22]. Thus, most likely, our questionnaire
captured[90% of the total caffeine consumption in Nord-
Trøndelag County.
The questionnaire-based headache diagnoses were not
optimal compared with the interview diagnosis [18]. The
bias caused by misclassification can either exaggerate or
underestimate the true difference between headache
groups. Most likely, any real difference between migraine
and non-migrainous headache sufferers with regard to
caffeine consumption will be underestimated because of
the presence of migraineurs in the non-migrainous head-
ache group and vice versa, making the two groups more
similar than they really are. The impact of non-participants
has been discussed in more details previously, and the fact
that neither headache nor caffeine consumption questions
were the primary objectives of the study makes selective
participation unlikely.
Conclusions
In this large cross-sectional study high caffeine consump-
tion was associated with increased prevalence of infrequent
headache, whereas chronic headache surprisingly was less
likely among individual with high caffeine consumption.
The results may indicate that high caffeine consumption
changes chronic headache into infrequent headache due to
the analgesic properties of caffeine. Alternatively, chronic
headache sufferers have reduced the intake of coffee and
tea to avoid worsening, whereas individuals with infre-
quent headache may be less aware that high caffeine use
can cause headache.
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